Funding Through Public Offerings and Third-Party Allotments
First written in FY2016. 11 of 14 entries say "Advanced", first in FY2017-Q3. Latest entry: FY2021.
22 other companies' latest entry also says "Achieved".
- FY2021AchievedAnnual report
「Number of such convertible bonds with stock acquisition rights and other instruments with provisions for adjustment of the exercise price exercised during the period: 1,300,000. Number of shares delivered upon exercise during the period: 1,300,000. Funds raised through exercise during the period: ¥1,443.450 million.」
With respect to the 18th Series Stock Acquisition Rights, 1,300,000 were exercised during the fiscal year, 1,300,000 shares were issued, and ¥1,443.450 million was raised. Cumulative funds raised totaled ¥1,444.776 million, and the exercise of the stock acquisition rights was reported as completed. - FY2021-Q2AdvancedAnnual report
「Number of such convertible bonds with stock acquisition rights and other instruments with provisions for adjustment of the exercise price exercised during the quarter: 1,250,000. Number of shares delivered upon exercise during the quarter: 1,250,000. Funds raised through exercise during the quarter: ¥1,376.400 million.」
Of the 18th Series Stock Acquisition Rights, 1,250,000 were exercised during the quarter, 1,250,000 shares were issued, and ¥1,376.400 million was raised. Cumulative exercises totaled 1,300,000 rights and cumulative funds raised totaled ¥1,444.776 million, while share capital and capital surplus each increased by ¥722 million during the cumulative quarter. - FY2021-Q1AdvancedAnnual report
「Number of such convertible bonds with stock acquisition rights and other instruments with provisions for adjustment of the exercise price exercised during the quarter: 50,000. Number of shares delivered upon exercise during the quarter: 50,000. Funds raised through exercise during the quarter: ¥67.050 million. Some of the 18th Series Stock Acquisition Rights with provisions for adjustment of the exercise price issued by the Company through a private placement were exercised after the end of the cumulative first quarter and by 13 November 2020. Details are as follows: ① number exercised: 650,000; ② increase in share capital: ¥366 million; ③ increase in capital reserve: ¥366 million; ④ type and number of shares issued: 650,000 common shares.」
Of the 18th Series Stock Acquisition Rights, 50,000 were exercised during the quarter, raising ¥67.05 million. A further 650,000 were exercised after the quarter-end through 13 November 2020, increasing share capital and the capital reserve by ¥366 million each. - FY2020AdvancedAnnual report
「Number of such convertible bonds with stock acquisition rights and other instruments with provisions for adjustment of the exercise price exercised during the period: 1,300,000. Number of shares delivered upon exercise during the period: 1,300,000. Funds raised through exercise during the period: ¥463.150 million.」
With respect to the 17th Series Stock Acquisition Rights, 1,300,000 were exercised during the fiscal year and 1,300,000 shares were issued. Cumulative funds raised totaled ¥464.619 million, and share capital and the capital reserve increased by ¥232.309 million each. - FY2020-Q2AdvancedAnnual report
「Number of such convertible bonds with stock acquisition rights and other instruments with provisions for adjustment of the exercise price exercised during the quarter: 1,200,000. Number of shares delivered upon exercise during the quarter: 1,200,000. Funds raised through exercise during the quarter: ¥426.006 million.」
Of the 17th Series Stock Acquisition Rights, 1,200,000 were exercised during the quarter, 1,200,000 shares were issued, and ¥426 million was raised. Cumulatively, 1,300,000 rights had been exercised and ¥464 million had been raised, while share capital and the capital reserve increased by ¥232 million each during the cumulative second quarter. - FY2020-Q1AdvancedAnnual report
「Number of such convertible bonds with stock acquisition rights and other instruments with provisions for adjustment of the exercise price exercised during the quarter: 100,000. Number of shares delivered upon exercise during the quarter: 100,000. Some of the 17th Series Stock Acquisition Rights with provisions for adjustment of the exercise price issued by the Company through a private placement were exercised after the end of the cumulative first quarter and by 13 November 2019: ① number exercised: 550,000; ② increase in share capital: ¥103 million; ③ increase in capital reserve: ¥103 million; ④ type and number of shares issued: 550,000 common shares.」
Of the 17th Series Stock Acquisition Rights issued through a private placement, 100,000 rights were exercised during the quarter, and a further 550,000 were exercised after the quarter-end through 13 November 2019. Exercise during the quarter increased share capital and the capital reserve by ¥19 million each, while the subsequent exercise increased each by ¥103 million. - FY2019AdvancedAnnual report
「1 July 2018–30 June 2019 (Note 4) 2,000,000 25,066,900 287,125 3,689,024 287,125 1,723,830」
Exercise of the 16th Series Stock Acquisition Rights resulted in the issuance of 2,000,000 shares and increased share capital and the capital reserve by ¥287 million each. The amount raised was ¥574 million. - FY2019-Q3AdvancedAnnual report
「The issuance of new shares upon the exercise of stock acquisition rights issued through a private placement increased share capital and capital surplus by ¥287 million each during the cumulative third quarter. At the end of the third quarter, share capital was ¥3,689 million and capital surplus was ¥1,596 million.」
Exercise of the stock acquisition rights issued through a private placement progressed, increasing share capital and capital surplus by ¥287 million each during the cumulative third quarter. - FY2019-Q2AdvancedAnnual report
「The issuance of new shares upon the exercise of stock acquisition rights issued through a private placement increased share capital and capital surplus by ¥244 million each during the cumulative second quarter. At the end of the second quarter, share capital was ¥3,646 million and capital surplus was ¥1,554 million.」
Exercise of the stock acquisition rights issued through a private placement increased share capital and capital surplus by ¥244 million each during the cumulative quarter. 1,540,000 shares were issued during the quarter, and a further 360,000 rights were exercised after the quarter-end. - FY2019-Q1AdvancedAnnual report
「The issuance of new shares upon the exercise of stock acquisition rights issued through a private placement increased share capital and the capital reserve by ¥17 million each. With respect to the 16th Series Stock Acquisition Rights with provisions for adjustment of the exercise price issued by the Company through a private placement, some rights were exercised after the end of the cumulative first quarter and by the end of October 2018: ① Number of stock acquisition rights exercised: 730,000; ② increase in share capital: ¥116 million; ③ increase in capital reserve: ¥116 million; ④ type and number of shares issued: 730,000 common shares.」
Of the stock acquisition rights issued through a private placement, 100,000 shares were issued upon exercise during the quarter, and a further 730,000 rights were exercised by the end of October 2018 after the quarter-end. Increases in share capital and the capital reserve were also reported, indicating progress in the financing. - FY2018AdvancedAnnual report
「At a meeting of the Company’s Board of Directors held on 27 August 2018, the Company resolved to issue, through a private placement, the 16th, 17th, and 18th Series Stock Acquisition Rights with provisions for adjustment of the exercise price, and to enter into a commitment agreement after the filing under the Financial Instruments and Exchange Act became effective. Payment of the total issue price of the stock acquisition rights was completed on 12 September 2018.」
Following the previous private placement, the Company approved and carried out a private placement of 4,600,000 stock acquisition rights to EVO FUND. The funds raised were ¥1,858.700 million, to be used for developing testing reagents, mass production and cost reduction, and working capital. - FY2017AchievedAnnual report
「On 31 May 2017, the Company issued 2,310,000 common shares through a paid-in private placement, increasing share capital and the capital reserve by ¥429.290 million each.」
The private placement with Hitachi High-Tech as the allottee was completed, raising ¥858,580,800 through the issuance of 2,310,000 shares. - FY2017-Q3AdvancedAnnual report
「At a meeting of the Company’s Board of Directors held on 15 May 2017, the Company resolved to enter into a capital and business alliance with 株式会社日立ハイテクノロジーズ (Hitachi High-Technologies; Hitachi High-Tech) and issue new shares to the company through a private placement. Through this private placement, the Company will allot 2,310,000 common shares to Hitachi High-Tech, representing 10.02% of voting rights and 10.01% of issued shares after the placement. The payment date is 31 May 2017. The funds are scheduled to be used in part to develop a fully automated genetic testing system for the IVD market, new products to expand the reagent lineup, and new technologies.」
A private placement with Hitachi High-Tech as the allottee was approved, specifying the raising of funds through 2,310,000 shares, representing 10.02% of voting rights, for total proceeds of ¥858,580,800, and their use for developing systems and reagents for the IVD market. - FY2016First statedAnnual report
「Due to increases in funds, including ¥1,501 million in proceeds from the issuance of shares, cash flow from financing activities increased by ¥1,123 million.」
Proceeds from the issuance of shares through a public offering in September 2015 and a private placement in October 2015 were used as a source of funds for capital investment and other purposes.